Latest news

• As France protests, Sanofi takes axe to 670 jobs

  dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

• Dupixent helps put Sanofi back on growth track

  Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

• Sanofi’s latecomer PD-1 gets date for FDA verdict

  The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... Regeneron-partnered cemiplimab is the first of the

• Sanofi’s PD-1 inhibitor starts EU review for skin cancer

  Sanofi has filed cemiplimab in the first instance as a treatment for advanced cutaneous squamous cell carcinoma (CSCC), which it says is the “deadliest form of non-melanoma skin cancer”. ... As of yet, none of the other PD-1/PD-L1-targeting drugs are

• Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

  CSCC is the second deadliest skin cancer after melanoma, and while quite treatable if caught early it is very serious in the advanced stages. ... Advanced CSCC is responsible for 3, 900 to 8, 800 deaths per year in the US,” said Regeneron’s clinical